Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

891 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adrenal Insufficiency Related to Anti-Programmed Death-1 Therapy.
Ariyasu R, Horiike A, Yoshizawa T, Dotsu Y, Koyama J, Saiki M, Sonoda T, Nishikawa S, Kitazono S, Yanagitani N, Nishio M. Ariyasu R, et al. Among authors: yoshizawa t. Anticancer Res. 2017 Aug;37(8):4229-4232. doi: 10.21873/anticanres.11814. Anticancer Res. 2017. PMID: 28739711
Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer.
Koyama J, Horiike A, Yoshizawa T, Dotsu Y, Ariyasu R, Saiki M, Sonoda T, Uchibori K, Nishikawa S, Kitazono S, Yanagitani N, Ninomiya H, Ishikawa Y, Nishio M. Koyama J, et al. Among authors: yoshizawa t. J Thorac Dis. 2019 May;11(5):1919-1928. doi: 10.21037/jtd.2019.04.102. J Thorac Dis. 2019. PMID: 31285885 Free PMC article.
Association of High Neutrophil-to-Lymphocyte Ratio With Poor Outcomes of Pembrolizumab Therapy in High-PD-L1-expressing Non-small Cell Lung Cancer.
Hasegawa T, Yanagitani N, Utsumi H, Wakui H, Sakamoto H, Tozuka T, Yoshida H, Amino Y, Uematsu S, Yoshizawa T, Uchibori K, Kitazono S, Horiike A, Horai T, Kuwano K, Nishio M. Hasegawa T, et al. Among authors: yoshizawa t. Anticancer Res. 2019 Dec;39(12):6851-6857. doi: 10.21873/anticanres.13902. Anticancer Res. 2019. PMID: 31810952
Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors.
Tozuka T, Kitazono S, Sakamoto H, Yoshida H, Amino Y, Uematsu S, Yoshizawa T, Hasegawa T, Uchibori K, Yanagitani N, Horiike A, Horai T, Seike M, Gemma A, Nishio M. Tozuka T, et al. Among authors: yoshizawa t. BMC Cancer. 2020 Mar 12;20(1):207. doi: 10.1186/s12885-020-6704-z. BMC Cancer. 2020. PMID: 32164651 Free PMC article.
Poor efficacy of anti-programmed cell death-1/ligand 1 monotherapy for non-small cell lung cancer patients with active brain metastases.
Tozuka T, Kitazono S, Sakamoto H, Yoshida H, Amino Y, Uematsu S, Yoshizawa T, Hasegawa T, Ariyasu R, Uchibori K, Yanagitani N, Horai T, Seike M, Gemma A, Nishio M. Tozuka T, et al. Among authors: yoshizawa t. Thorac Cancer. 2020 Sep;11(9):2465-2472. doi: 10.1111/1759-7714.13557. Epub 2020 Jul 12. Thorac Cancer. 2020. PMID: 32657011 Free PMC article.
Association between continuous decrease of plasma VEGF-A levels and the efficacy of chemotherapy in combination with anti-programmed cell death 1 antibody in non-small cell lung cancer patients.
Tozuka T, Yanagitani N, Sakamoto H, Yoshida H, Amino Y, Uematsu S, Yoshizawa T, Hasegawa T, Ariyasu R, Uchibori K, Kitazono S, Seike M, Gemma A, Nishio M. Tozuka T, et al. Among authors: yoshizawa t. Cancer Treat Res Commun. 2020;25:100249. doi: 10.1016/j.ctarc.2020.100249. Epub 2020 Nov 21. Cancer Treat Res Commun. 2020. PMID: 33249211 Free article.
891 results